🏢 官网IRRXSTDoubao · 实盘不做把握 9/10不做原因:无增量信息🔁 +1 同一事件
北京时间·🕒 发布 04:05:13(美东 10-20 16:05)·⟳ 抓取 04:05:46回填·⚡ 决策 10-21 04:08:29 +3m16s·6.8 天前
RxSight 公告将于11月3日盘后发布2026年三季报，仅为财报日期通知
该IR稿只是例行财报日期通知（11月3日盘后发财报），不含任何业绩数字、指引或经营信息，无预期差、无方向，Web/KB/行情/先例均不可能将其变成可交易事件；真正的催化要等11月3日财报本身。
📄 原文RXST↗ 原文
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
PDF Version ALISO VIEJO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that…
不做 RxSight, Inc.（RXST.US）
纯财报日期通知（Q3 2026业绩将于11月3日盘后发布），无任何收入、利润、指引或订单增量，无预期差与方向，不构成事件驱动交易；待实际财报发布后再研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
RxSight仅公告Q3财报将于11月3日盘后发布，无任何财务或经营增量，属例行日程通知，不构成事件驱动交易机会，回避。
🔎 新鲜度:最早出现 2026-10-20 · 扩散 low · price-in 风险 low ↗
主要风险
- 真正的波动来自11月3日财报及管理层指引，届时需基于实际数据与一致预期另行研判，不应提前以本通知建仓。
先例如何影响了这次决策
对本次决策的影响:未影响决策；事件本身无增量，直接回避，等待11月3日财报
方向:无可读方向：财报日期通知无基本面内容，先例不适用
涨幅量级:无对齐先例，也无需校准幅度
形态:不适用
原文全文
展开原文 · 1,459 字
PDF Version
ALISO VIEJO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) --
(NASDAQ: RXST) –
RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on Tuesday, November 3, 2026. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 8782462. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at
https://investors.rxsight.com/
. An archived recording of the call will be available through the same link shortly after its completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The Light Adjustable Lens™ system, comprised of the RxSight Light Adjustable Lens™ products (LAL™ and LAL+™), RxSight Light Delivery Device™ (LDD™), and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at
www.rxsight.com
.
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
ALISO VIEJO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) --
(NASDAQ: RXST) –
RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on Tuesday, November 3, 2026. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 8782462. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at
https://investors.rxsight.com/
. An archived recording of the call will be available through the same link shortly after its completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The Light Adjustable Lens™ system, comprised of the RxSight Light Adjustable Lens™ products (LAL™ and LAL+™), RxSight Light Delivery Device™ (LDD™), and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at
www.rxsight.com
.
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
32cbbde456· 2026-10-21 04:08 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前